After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, BEAM falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Beam Therapeutics Inc is $1.68B. A total of 2.39 million shares were traded on the day, compared to an average of 2.25M shares.
In the most recent transaction, FMR LLC sold 48,374 shares of BEAM for 20.50 per share on Jul 30 ’25. After the transaction, the insider now owns 2,073,665 company shares. In a previous transaction on Jul 03 ’25, Simon Amy sold 876 shares at 20.12 per share. BEAM shares that Chief Medical Officer owns now total 64,864.
Among the insiders who sold shares, Simon Amy disposed of 374 shares on Jul 01 ’25 at a per-share price of $16.94. This resulted in the Chief Medical Officer holding 65,740 shares of BEAM after the transaction. In another insider transaction, Bellon Christine sold 5,674 shares at $18.35 per share on Apr 01 ’25. Company shares held by the Chief Legal Officer now total 117,294.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, BEAM has a high of $35.25 and a low of $13.52.
As of this writing, BEAM has an earnings estimate of -$1.02 per share for the current quarter. EPS was calculated based on a consensus of 10.0 estimates, with a high estimate of -$0.79 per share and a lower estimate of -$1.16. The company reported an EPS of -$1.17 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. BEAM’s latest balance sheet shows that the firm has $965.65M in Cash & Short Term Investments as of fiscal 2021. There were $142.35M in debt and $213.44M in liabilities at the time. Its Book Value Per Share was $10.39, while its Total Shareholder’s Equity was $826.74M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BEAM is Buy with a score of 4.56.
